Decreased immunoreactive maspin expression in intermediate thickness and thick primary melanoma lesions

Journal of International Medical Research

Volumn 34, Issue 1, 2006, Pages 52-57

  Vereecken, Pierre ^a,b,c,f   Reynaert, S ^a   Lalmand, M C ^d   Zouaoui Boudjeltia, K ^c   Heenen, M ^a   Van Den Heule, B ^e   Petein, M ^d  

^a ERASME HOSPITAL   (Belgium)

^b JULES BORDET INSTITUTE   (Belgium)

^c CHU Andre Vesale   (Belgium)

^d Institute of Pathology and Genetics Gosselies   (Belgium)

^e Ctr de Morphologie et de Pathologie   (Belgium)

^f NONE   (Belgium)

Author keywords

Maspin; Melanoma; Protease inhibitor; Tumour progression

Indexed keywords

CITRIC ACID; MASPIN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ANTIGEN RETRIEVAL; ARTICLE; CANCER INVASION; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS POTENTIAL; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; SCORING SYSTEM;

EID: 33645297930     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000603400106     Document Type: Article

References (31)

1. Umekita Y, Ohi Y, Sagara Y, Yoshida H: Expression of maspin predicts poor prognosis in breast cancer patients. Int J Cancer 2002; 100: 452-455.
2. Zhang M, Volpert O, Shi YH, Bouck N: Maspin is an angiogenesis inhibitor. Nat Med 2000; 6: 196-199.
3. Machtens S, Serth J, Bokemeyer C, Bathke W, Minssen A, Kollmannsberger C, et al: Expression of the p53 and maspin protein in primary prostate cancer: correlation with clinical features. Int J Cancer 2001; 95: 337-342.
4. Biliran H, Sheng S: Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by tumor suppressive maspin. Cancer Res 2001; 61: 8676-8682.
5. Umekita Y, Yoshida H: Expression of maspin is up-regulated during the progression of mammary ductal carcinoma. Histopathology 2003; 42: 541-545.
6. Boltze C, Schneider-Stock R, Quednow C, Gerlach R, Mawrin C, Hinze R, et al: Proteome analysis identified maspin as a special feature of papillary thyroid carcinoma. Int J Oncol 2003; 23: 1323-1328.
7. Pierson CR, McGowen R, Grignon D, Sakr W, Dey J, Sheng S: Maspin is up-regulated in premalignant prostate epithelia. Prostate 2002; 53: 255-262.
8. Chen Z, Fan Z, McNeal JE, Nolley R, Caldwell MC, Mahadevappa M, et al: Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer. J Urol 2003; 169: 1316-1319.
9. Smith SL, Watson SG, Ratschiller D, Gugger M, Betticher DC, Heighway J: Maspin - the most commonly-expressed gene of the 18q21.3 serpin cluster in lung cancer - is strongly expressed in preneoplastic bronchial lesions. Oncogene 2003; 22: 8677-8687.
10. Hojo T, Akiyama Y, Nagasaki K, Maruyama K, Kikuchi K, Ikeda T, et al: Association of maspin expression with the malignancy grade and tumor vascularization in breast cancer tissues. Cancer Lett 2001; 171: 103-110.
11. Mohsin SK, Zhang M, Clark GM, Allred D: Maspin expression in invasive breast cancer: association with other prognostic factors. J Pathol 2003; 199: 432-435.
12. Maass N, Hojo T, Rösel F, Ikeda T, Jonat W, Nagasaki K: Down regulation of the tumor suppressor gene maspin in breast carcinoma is associated with a higher risk of distant metastasis. Clin Biochem 2001; 34: 303-307.
13. Maass N, Teffner M, Rösel F, Pawaresch R, Jonat W, Nagasaki K, et al: Decline in the expression of the serine proteinase inhibitor maspin is associated with tumour progression in ductal carcinomas of the breast. J Pathol 2001; 195: 321-326.
14. Shi HY, Zhang W, Liang R, Abraham S, Kittrell FS, Medina D, et al: Blocking tumor growth, invasion, and metastasis by maspin in a syngeneic breast cancer model. Cancer Res 2001; 61: 6945-6951.
15. Seftor RE, Seftor EA, Sheng S, Pemberton PA, Sager R, Hendrix MJ: Maspin suppresses the invasive phenotype of human breast carcinoma. Cancer Res 1998; 58: 5681-5685.
16. Bièche I, Girault I, Sabourin JC, Tozlu S, Driouch K, Vidaud M, et al: Prognostic value of maspin mRNA expression in ER alpha-positive postmenopausal breast carcinomas. Br J Cancer 2003; 88: 863-870.
17. Khalkhali-Ellis Z, Christian AL, Kirschmann DA, Edwards EM, Rezaie-Thompson M, Vasef MA, et al: Regulating the tumor suppressor gene maspin in breast cancer cells: a potential mechanism for the anticancer properties of tamoxifen. Clin Cancer Res 2004; 10: 449-454.
18. Sood AK, Fletcher MS, Gruman LM, Coffin JE, Jabbari S, Khalkhali-Ellis Z, et al: The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res 2002; 8: 2924-2932.
19. Ohike N, Maass N, Mundhenke C, Biallek M, Zhang M, Jonat W, et al: Clinicopathological significance and molecular regulation of maspin expression in ductal adenocarcinoma of the pancreas. Cancer Lett 2003; 199: 193-200.
20. Wada K, Maesawa C, Akasaka T, Masuda T: Aberrant expression of the maspin gene associated with epigenetic modification in melanoma cells. J Invest Dermatol 2004; 122: 805-811.
21. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli M, Coit DG, et al: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635-3648.
22. Vereecken P, Debray C, Petein M, Awada A, Lalmand M-C, Laporte M, et al: Expression of galectin-3 in primary and metastatic melanoma: immunohistochemical studies on human lesions and nude mice xenograft tumors. Arch Dermatol Res 2005; 296: 353-358.
23. Reis-Filho JS, Torio B, Albergaria A, Schmitt FC: Maspin expression in normal skin and usual cutaneous carcinomas. Virchows Arch 2002; 441: 551-558.
24. Breslow A: Prognosis in cutaneous melanoma: tumor thickness as a guide to treatment. Pathol Annu 1980; 15 (Pt1): 1-22.
25. Ruiter DJ, van Muijen GN: Markers of melanocytic tumour progression. J Pathol 1998; 186: 340-342.
26. Hendrix MJ: De-mystifying the mechanism(s) of maspin. Nat Med 2000; 6: 374-376.
27. Westermarck J, Kahari VM: Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999; 13: 781-792.
28. Gui GP, Puddefoot JR, Vinson GP, Wells CA, Carpenter R: Altered cell-matrix contact: a prerequisite for breast cancer metastasis? Br J Cancer 1997; 75: 623-633.
29. Sheng S, Truong B, Fredrickson D, Wu R, Pardee AB, Sager R: Tissue-type plasminogen activator is a target of the tumor suppressor gene maspin. Proc Natl Acad Sci USA 1998; 95: 499-504.
30. Futscher BW, Oshiro MM, Wozniak RJ, Holton N, Hanigan CL, Duan H, et al: Role for DNA methylation in the control of cell type specific maspin expression. Nat Genet 2002; 31: 175-179.
31. Domann FE, Futscher BW: Editorial: maspin as a molecular target for cancer therapy. J Urol 2003; 169: 1162-1164.